Large Canada ICES dataset- DMARD use is not associated with adverse pregnancy outcomes. In pts with RA, SlE and other rheumatic diseases. Abst#2627 #ACR25 @RheumNow https://t.co/T9Ll1FNjT7

• https://x.com/bella_mehta/status/1983266032837156870/photo/1
• https://x.com/bella_mehta/status/1983266032837156870/photo/1

#1748 Higher air pollution, esp PM2.5, linked to ⬆️RA disease activity and more flares in >1000 Korean patients. Each rise in PM2.5 significantly boosted DAS28, CDAI & joint counts. Does cleaner air mean calmer joints? @RheumNow #ACR25

US Electronic Health Record cohort 2000+pts Incidence Heart Failure over 10 yrs 6.8% HF asso w/ Older Male Lower eGFR Hypertensive medication Diabetes TTMTS MTX, TNFi Higher CRP Probably surrogates for High Disease Activity... How do we detect it? Maybe not by using the https://t.co/s9SjEyk3WF

• https://x.com/AurelieRheumo/status/1983242428447424710/photo/1
• https://x.com/AurelieRheumo/status/1983242428447424710/photo/1

Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #ACR25 Abstr#2338 https://t.co/Y0B3W4csJX

• https://x.com/RichardPAConway/status/1983230783952466190/photo/1

In RA, “strong bones” can give false reassurance. Pts with higher baseline BMD had faster bone loss, often tied to GC use and less osteoporosis treatment. Undermanagement, not biology, may drive decline. @RheumNow #ACR25 Abstract#2244 https://t.co/N421ESAUy9

• https://x.com/JihaRheum/status/1983230532231332183/photo/1

After melanoma, should RA patients stop DMARDs? These VA data (n=644) showed no mortality signal, and trending to survival benefit with b/tsDMARDs Provisos over methotrexate, invasive disease etc, but don’t hold off treating the RA because of melanoma #ACR25 ABST2237 @RheumNow https://t.co/l9n1V6YVln

• https://x.com/drdavidliew/status/1983229116469162290/photo/1

Can a Fitbit track RA? This Japanese clinic is using Fitbit data and have seen it correlate with CDAI across their RA clinic. Maybe instead of asking about our patients mobility and sleep, we should be measuring it? #ACR25 ABST2253 @RheumNow https://t.co/rg2SKgn7K2

• https://x.com/drdavidliew/status/1983227402605211728/photo/1

#1751 In early RA, higher disease activity, inflammation & older age linked to more ILD changes on machine-learning chest CT. Even subtle QCT abnormalities correlated with reduced lung function pointing to early inflammatory pathways in RA-ILD. @RheumNow #ACR25

Are the clues of RA there in the EMR, before the diagnosis is made? Jina off-the-shelf AI with subsequent retraining found the digital fingerprint of RA in @MayoClinic medical notes, years before formal diagnosis. The clues are there #ACR25 ABST2260 @MyasoedovaElena @RheumNow https://t.co/onGlKUmefd

• https://x.com/drdavidliew/status/1983225667119419748/photo/1

In the CLOSE-UP study of UPA in RA - 61% in remission with responses sustained to 24 mo - Benefit consistent irrespective of prior DMARD use - No new safety signals @RheumNow #ACR25 Abstract#2281

Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. Progressive ILD in 23%. Similar to the numbers progressing on baricitinib by same group. Previous MTX treatment appears to REDUCE risk (OR 0.45). Disease activity increases risk (OR 1.29). @RheumNow #ACR25 Abstr#2265 https://t.co/0tl0kGgm5p

• https://x.com/RichardPAConway/status/1983218705136800239/photo/1

Starting biologic early could save more than joints. In 329 RA pts, first-line anti-TNF reduced testing and hospitalization costs vs csDMARDs across Europe. Earlier targeted therapy pay off in outcomes and economics. @RheumNow #ACR25 Abstract#2271 https://t.co/zZ32CpT36d

• https://x.com/JihaRheum/status/1983217698508013990/photo/1

#1747 Serious infections ~2× more common in RA-LD, esp RA-ILD. Pulmonary, bacterial, viral & fungal infections all increased, underscoring need for tailored prevention and vaccination. @RheumNow #ACR25 https://t.co/soyzqLk7Vj

• https://x.com/DrMiniDey/status/1983215181129031750/photo/1

#1746 In large US RA cohort, elevated GDF-15 & pentraxin-3 levels linked to prevalent RA-ILD; high GDF-15 predicted future ILD risk. Other fibrosis-related mediators from IPF or heart failure were not associated, suggesting RA-ILD has distinct pathogenic pathways @RheumNow #ACR25